Diabetes

Carbon monoxide therapy for TIIDM and obesity-associated metabolic deficits: COR-M2(CO releasing molecule-2) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 12/June/2018, 9.31 pm
Carbon monoxide therapy for TIIDM and obesity-associated metabolic deficits: COR-M2(CO releasing molecule-2) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 12/June/2018, 9.31 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Treating blood sugar disease with low-calorie sweeteners: Xylitol-based therapy for diabetes (TIIDM): Xylitol , a low-calorie sweetener isolated from natural products, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 12/June/2018, 9.23 pm
Treating blood sugar disease with low-calorie sweeteners: Xylitol-based therapy for diabetes (TIIDM): Xylitol , a low-calorie sweetener isolated from natural products, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 12/June/2018, 9.23 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Treating blood sugar disease with low-calorie sweeteners: D-Allulose-based therapy for diabetes (TIIDM): D-Allulose/D-Psicose, a low-calorie sweetener isolated from natural products, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 9/June/2018, 10.32 pm
Treating blood sugar disease with low-calorie sweeteners: D-Allulose-based therapy for diabetes (TIIDM): D-Allulose/D-Psicose, a low-calorie sweetener isolated from natural products, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 9/June/2018, 10.32 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Interleukin-based therapy for body weight control, energy homeostasis and TIIDM: Interleukin-2(IL-2) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 7/June/2018, 6.38 am
Interleukin-based therapy for body weight control, energy homeostasis and TIIDM: Interleukin-2(IL-2) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 7/June/2018, 6.38 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more

Cluster of differentiation-based therapy for body weight control, energy homeostasis and TIIDM: Cluster of differentiation (CD24) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 6/June/2017, 11.52 pm
Cluster of differentiation-based therapy for body weight control, energy homeostasis and TIIDM: Cluster of differentiation (CD24) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 6/June/2017, 11.52 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more

Interleukin-based therapy for body weight control, energy homeostasis and TIIDM: Interleukin-15 (IL-15) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 3/June/2017, 11.08 pm
Interleukin-based therapy for body weight control, energy homeostasis and TIIDM: Interleukin-15 (IL-15) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 3/June/2017, 11.08 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more
Start Typing